Insurance Expansion Improved Care for Colorectal Cancer
The expansion of healthcare in Massachusetts in 2006 was associated with increased rates of resection for patients with colorectal cancer.
Benefits of Colon Cancer Screening Decrease After Age 75
Colonoscopy screening is modestly effective for preventing colorectal cancer in patients aged 70 to 74, but the benefits may begin to diminish after that.
Common Mutations May Lead to Worse CRC Outcomes in African-Americans
A set of genes that are more likely to be mutated in African-Americans vs Caucasians with colorectal cancer appears to increase the risk of metastases and relapse in mutant versions.
Could Gene Assay Help Guide Stage II Colon Cancer Treatment?
In this interview we discuss the GeneFx Colon test (or the ColDx assay), which can helpful identify patients with low- or high-risk stage II colon cancer.
ColDx Assay May Help Refine Prognosis in Stage II Colon Cancer
A gene expression microarray-based assay was able to successfully identify patients with stage II colon cancer who are at high risk for recurrence.
Mouth Bacteria Can Worsen Colorectal Cancer
A study found that fusobacteria, commonly found in the mouth, can enrich colorectal cancer cells, in a process mediated by the Fap2 protein.
Anti–PD-L1 Immunotherapy, MEK Inhibition Active in Metastatic CRC
Combination treatment with the MEK inhibitor cobimetinib and the anti–PD-L1 drug atezolizumab was active in patients with microsatellite-stable metastatic colorectal cancer.
Location of Primary Tumor Matters in Colorectal Cancer
A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.
RECOURSE Study Finds TAS-102 Effective in Colorectal Cancer
In this video, Dr. Atsushi Ohtsu discusses the use of TAS-102, an oral combination of trifluridine and tipiracil hydrochloride, in refractory colorectal cancer.
Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Assessment of Colorectal Cancer Screening Awareness, Preferences in Jordan
In this video from the 2015 ONS meeting, Dr. Omran discusses the high-risk of colorectal cancer among the Jordanian population and the need to promote more screening awareness.
By clicking Accept, you agree to become a member of the UBM Medica Community.